1% alendronate gel as local drug delivery in the treatment of class II furcation defects: A randomized controlled clinical trial

Journal of Periodontology

Volumn 84, Issue 3, 2013, Pages 307-315

  Pradeep, A R ^a   Kumari, Minal ^a   Rao, Nishanth S ^a   Naik, Savitha B ^a  

^a GOVERNMENT DENTAL COLLEGE AND RESEARCH INSTITUTE   (India)

Author keywords

Alendronate; Clinical trial; Drug delivery systems; Furcation defects; Radiography

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; BONE REGENERATION; CHI SQUARE DISTRIBUTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; GEL; HUMAN; MALE; MANDIBLE; MIDDLE AGED; PERIODONTAL DISEASE; PERIODONTICS; PREVENTIVE DENTISTRY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; CHI-SQUARE DISTRIBUTION; DENTAL SCALING; DRUG DELIVERY SYSTEMS; FEMALE; FURCATION DEFECTS; GELS; HUMANS; MALE; MANDIBLE; MIDDLE AGED; PERIODONTAL INDEX;

EID: 84874633511     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2012.110729     Document Type: Article

References (52)

1. Chapple IL, Matthews JB. The role of reactive oxygen and antioxidant species in periodontal tissue destruction. Periodontol 2000 2007;43: 160-232.
2. Lindhe J, Okamoto H, Yoneyama T, Haffajee A, Socransky SS. Periodontal loser sites in untreated adult subjects. J Clin Periodontol 1989;16: 671-678.
3. Becker W, Berg L, Becker BE. Untreated periodontal disease: A longitudinal study. J Periodontol 1979;50: 234-244.
4. Papapanou PN, Wennström JL, Gröndahl K. A 10-year retrospective study of periodontal disease progression. J Clin Periodontol 1989;16: 403-411. (Pubitemid 19212729)
5. DeSanctis M, Murphy KG. The role of resective periodontal surgery in the treatment of furcation defects. Periodontol 2000 2000;22: 154-168.
6. Karring T, Cortellini P. Regenerative therapy: Furcation defects. Periodontol 2000 1999;19: 115-137.
7. Müller HP, Eger T, Lange DE. Management of furcation- involved teeth. A retrospective analysis. J Clin Periodontol 1995;22: 911-917.
8. Kalkwarf KL, Kaldahl WB, Patil KD. Evaluation of furcation region response to periodontal therapy. J Periodontol 1988;59: 794-804.
9. Carnevale G, Pontoriero R, Lindhe J. Treatment of furcation-involved teeth. In: Lindhe J, ed. Clinical Periodontology and Implant Dentistry, 3rd ed. Copenhagen: Munksgaard; 1997: 683-710.
10. Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res 1993;8 (Suppl. 2):S565-S572. (Pubitemid 24015250)
11. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42: 919-944. (Pubitemid 21920790)
12. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(Suppl. 12): 2961-2978. (Pubitemid 30413179)
13. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998;22: 455-461.
14. Vitté C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast- mediated resorption. Endocrinology 1996;137: 2324-2333.
15. Goziotis A, Sukhu B, Torontali M, Dowhaniuk M, Tenenbaum HC. Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone 1995;16 (Suppl. 4):317S-327S.
16. Tenenbaum HC, Torontali M, Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 1992;13: 249-255.
17. Tenenbaum HC, Shelemay A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: Potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 2002;73: 813-822.
18. Yaffe A, Fine N, Alt I, Binderman I. The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats. J Periodontol 1995;66: 999-1003.
19. Yaffe A, Fine N, Binderman I. Regional accelerated phenomenon in the mandible following mucoperiosteal flap surgery. J Periodontol 1994;65: 79-83.
20. Reddy GT, Kumar TM, Veena KM. Formulation and evaluation of Alendronate Sodium gel for the treatment of bone resorptive lesions in Periodontitis. Drug Deliv 2005;12: 217-222. (Pubitemid 40981284)
21. Binderman I, Adut M, Yaffe A. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats. J Periodontol 2000;71: 1236-1240. (Pubitemid 30655955)
22. Yaffe A, Iztkovich M, Earon Y, Alt I, Lilov R, Binderman I. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats. J Periodontol 1997;68: 884-889. (Pubitemid 27411022)
23. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009;8: 96-110.
24. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62: 527-534. (Pubitemid 38542516)
25. Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: A randomized, controlled clinical trial. J Periodontol 2012;83: 11-18.
26. Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis: A randomized controlled clinical trial. J Periodontol 2012;83: 19-26.
27. Lindhe J, Nyman S. The effect of plaque control and surgical pocket elimination on the establishment and maintenance of periodontal health. A longitudinal study of periodontal therapy in cases of advanced disease. J Clin Periodontol 1975;2: 67-79.
28. Hamp SE, Nyman S, Lindhe J. Periodontal treatment of multirooted teeth. Results after 5 years. J Clin Periodontol 1975;2: 126-135.
29. Mühlemann HR, Son S. Gingival sulcus bleeding - A leading symptom in initial gingivitis. Helv Odontol Acta 1971;15: 107-113.
30. Silness J, Löe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;22: 121-135.
31. Pradeep AR, Thorat MS. Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: A randomized clinical trial. J Periodontol 2010;81: 214-222.
32. Adami S, Zamberlan N, Mian M, et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone Miner 1994;25: 75-82. (Pubitemid 24181906)
33. Liberman UA, Weiss SR, Bröll J, et al The Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl JMed 1995;333: 1437-1443.
34. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88: 2095-2105.
35. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10: 1478-1487.
36. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990;5: 31-40. (Pubitemid 20089901)
37. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83: 1930-1935. (Pubitemid 19148862)
38. Colucci S, Minielli V, Zambonin G, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998;63: 230-235. (Pubitemid 28387975)
39. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structureactivity relationships in J774 macrophages. J Bone Miner Res 1998;13: 1668-1678. (Pubitemid 28491995)
40. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998;27: 38-41. (Pubitemid 28116468)
41. Teronen O, Heikkilä P, Konttinen YT, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999;878: 453-465. (Pubitemid 29353588)
42. Rocha M, Nava LE, Vázquez de la Torre C, Sánchez- Má rin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo-controlled trial. J Periodontol 2001;72: 204-209.
43. Meraw SJ, Reeve CM. Qualitative analysis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. J Periodontol 1999;70: 1228-1233. (Pubitemid 29485264)
44. Brunsvold MA, Chaves ES, Kornman KS, Aufdemorte TB, Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol 1992; 63: 825-830.
45. Lavanchy DL, Bickel M, Baehni PC. The effect of plaque control after scaling and root planing on the subgingival microflora in human periodontitis. J Clin Periodontol 1987;14: 295-299.
46. Loos B, Claffey N, Egelberg J. Clinical and microbiological effects of root debridement in periodontal furcation pockets. J Clin Periodontol 1988;15: 453-463.
47. Jepsen S, Eberhard J, Herrera D, Needleman I. A systematic review of guided tissue regeneration for periodontal furcation defects. What is the effect of guided tissue regeneration compared with surgical debridement in the treatment of furcation defects? J Clin Periodontol 2002;29(Suppl. 3): 103-116, discussion 160-162. (Pubitemid 41719446)
48. Needleman IG, Pandya NV, Smith SR, Foyle DM. The role of antibiotics in the treatment of periodontitis (Part 2-Controlled drug delivery). Eur J Prosthodont Restor Dent 1995;3: 111-117.
49. Greenstein G, Polson A. The role of local drug delivery in the management of periodontal diseases: A comprehensive review. J Periodontol 1998;69: 507-520. (Pubitemid 28255639)
50. Jones DS, Brown AF, Woolfson AD. Rheological characterization of bioadhesive, antimicrobial, semisolids designed for the treatment of periodontal diseases: Transient and dynamic viscoelastic and continuous shear analysis. J Pharm Sci 2001;90: 1978-1990. (Pubitemid 33144444)
51. Perioli L, Ambrogi V, Rubini D, et al. Novel mucoadhesive buccal formulation containing metronidazole for the treatment of periodontal disease. J Control Release 2004;95: 521-533. (Pubitemid 38340502)
52. Jones DS, Woolfson AD, Djokic J, Coulter WA. Development and mechanical characterization of bioadhesive semi-solid, polymeric systems containing tetracycline for the treatment of periodontal diseases. Pharm Res 1996;13: 1734-1738. (Pubitemid 26426902)